ALNY
Alnylam Pharmaceuticals, Inc. Common Stock
$236.17
장중 · Vol 5.7K · 52주 $197.81–$495.55 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $235.46 · Aug 31, 2026
ALNY 가격 추세
종가
$235.46
시가
$233.88
고가
$235.94
저가
$233.88
30초 브리핑
ALNY 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 13%
연중 저점권입니다. 반등 신호보다 하락 원인을 먼저 확인하세요.
Forward P/E 19.1배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.4배
거래량은 최근 평균 범위입니다.
2026-10-29
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
ALNY 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
675 West Kendall Street · Cambridge, MA, United States · 직원 2,500명
시가총액
$32.21B
Trailing P/E
41.9
최근 12개월 이익 기준
Forward P/E
19.1
이익 증가 기대 반영
EPS (TTM)
$5.74
배당 수익률
—
배당성향
0.0%
베타
0.28
시장보다 방어적
ROE
96.6%
P/B
23.77
EV/EBITDA
29.8
52주 범위
$197.81 – $495.55
현재 위치 13%
거래량
1.91M
20일 평균 1.39M · 1.4배
애널리스트 의견
매수 79%
총 28명 · 0m
DITM LEAPS Analysis
ALNY 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALNY271217C00130000 | 12/17/27 · 1.3Y | $130.00 | $126.75 | 1.7x | 0.8955 | 12.7% | 3.55% | 68.33% | 0 | 71.00 | |
| ALNY271217C00150000 | 12/17/27 · 1.3Y | $150.00 | $112.25 | 1.9x | 0.8615 | 19.2% | 4.01% | 65.19% | 289 | 69.85 | |
| ALNY271217C00160000 | 12/17/27 · 1.3Y | $160.00 | $105.25 | 1.9x | 0.8429 | 23.3% | 4.28% | 63.61% | 18 | 63.20 | |
| ALNY271217C00170000 | 12/17/27 · 1.3Y | $170.00 | $98.25 | 2.0x | 0.8235 | 28.1% | 4.58% | 61.83% | 5 | 57.79 | |
| ALNY271217C00180000 | 12/17/27 · 1.3Y | $180.00 | $92.00 | 2.1x | 0.8024 | 34.0% | 4.35% | 60.79% | 2 | 52.01 | |
| ALNY271217C00185000 | 12/17/27 · 1.3Y | $185.00 | $88.75 | 2.1x | 0.7916 | 37.3% | 5.07% | 60.03% | 2 | 49.30 | |
| ALNY271217C00190000 | 12/17/27 · 1.3Y | $190.00 | $86.00 | 2.2x | 0.7803 | 41.1% | 4.65% | 59.79% | 3 | 46.89 | |
| ALNY271217C00200000 | 12/17/27 · 1.3Y | $200.00 | $80.00 | 2.3x | 0.7575 | 49.1% | 5.00% | 58.55% | 24 | 43.00 |
재무제표
ALNY 연간 손익·현금흐름·재무상태
매출 성장률
+65.2%
최근 연간 YoY
EPS 성장률
+206.9%
최근 연간 YoY
영업이익률
13.5%
최근 연간
FCF 마진
12.5%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $3.71B+65.2% | $2.25B+23.0% | $1.83B+76.2% | $1.04B |
| 매출총이익 | $3.03B+57.5% | $1.92B+26.8% | $1.52B+74.8% | $868.60M |
| 영업이익 | $501.58M+383.6% | -$176.88M+37.3% | -$282.18M+64.1% | -$785.07M |
| 순이익 | $313.75M+212.8% | -$278.16M+36.8% | -$440.24M+61.1% | -$1.13B |
| 희석 EPS | $2.33+206.9% | $-2.18+38.1% | $-3.52+62.2% | $-9.30 |
| EBITDA | $631.44M+453.1% | -$178.85M+30.7% | -$258.24M+72.1% | -$926.56M |
| 영업현금흐름 | $524.08M+6405.1% | -$8.31M-108.0% | $104.16M+119.2% | -$541.27M |
| 잉여현금흐름 | $465.38M+1192.7% | -$42.59M-201.5% | $41.95M+106.8% | -$613.33M |
| 총자산 | $4.97B+17.1% | $4.24B+10.7% | $3.83B+8.0% | $3.55B |
| 총부채 | $1.28B-1.4% | $1.30B-0.7% | $1.31B-1.1% | $1.32B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
ALNY 실적·배당 일정
매출 하단
$1.39B
EPS 하단
$1.94
매출 상단
$1.49B
실적 발표일
2026-10-29
D-58
EPS 상단
$3.45
매출 컨센서스
$1.44B
EPS 컨센서스
$2.32
뉴스
ALNY 관련 최신 기사
- 일반
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
Alnylam Pharmaceuticals' (ALNY) latest data strengthen the case for Nucresiran and TRITON-CM success
MT Newswires · Aug 31, 2026
제품·기술Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself
Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicines that work with the body's natural complexity rather than against it. He discusses Inceptive's partnership with Alnylam Pharmaceuticals and why their RNA interference platform and rich data history make them a uniquely powerful AI collaborator. Uszkoreit explains why partnerships are essential for a small company with broadly applicable technology, and why the long-term prize is therapies that are gentler, earlier, and truly personalized.
NYSE · Aug 31, 2026
제품·기술IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.
Stocktwits · Aug 28, 2026
- 제품·기술
Alnylam stock drops on rival heart trial: Why analysts see core business safe
Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell on Friday. Shares of Alnylam (NASDAQ: ALNY) fell nearly 4.9% in pre-market trading following the full presentation of data from a rival drug trial at the European Society of Cardiology Congress in Munich. The detailed results from AstraZeneca and Ionis Pharmaceu
Investing.com · Aug 28, 2026
- 제품·기술
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
BioPharma Dive · Aug 28, 2026
실적Moderna Stock Carries A Market Value Its Revenue Does Not Support
Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.
Trefis · Aug 26, 2026
실적Alnylam Pharmaceuticals (ALNY) Stock Looks Cheap After A 47% Fall Yet Rich On Earnings
Alnylam Pharmaceuticals stock has fallen 46.8% over the past year, yet the valuation checks still flag it as leaning expensive rather than a clear bargain. With fresh clinical data on its RNAi programs coming at the ESC Congress 2026, investors are weighing that share price slump against what the current market valuation implies. The share price decline of 46.8% over the last 12 months signals that expectations have come down sharply and raises the question of whether sentiment has weakened...
Simply Wall St. · Aug 25, 2026
- 제품·기술
Alnylam Pharmaceuticals (ALNY) Heads To ESC With New Data, Is It A Bargain?
Alnylam Pharmaceuticals (ALNY) has drawn market attention after announcing plans to present new clinical and real-world data on its ATTR and hypertension RNAi programs at the ESC Congress 2026 in Munich. See our latest analysis for Alnylam Pharmaceuticals. Despite the ESC Congress announcement, Alnylam Pharmaceuticals’ share price has been under pressure, with the stock down 41% year to date and the 1 year total shareholder return declining 47%, although the 3 year total shareholder return...
Simply Wall St. · Aug 24, 2026
- 제품·기술
Is Alnylam (ALNY) Turning Expanded HELIOS-B and Zilebesiran Data Into Durable Cardiovascular Leadership?
Alnylam Pharmaceuticals announced it will present new clinical and real-world data on AMVUTTRA (vutrisiran) and investigational hypertension drug zilebesiran at the European Society of Cardiology Congress 2026 in Munich, following the release of detailed HELIOS-B and KARDIA-3 study analyses. The breadth of ATTR and hypertension data, spanning late-stage trials and real-world evidence, reinforces Alnylam’s RNAi platform reach across serious cardiovascular conditions. We’ll now examine how...
Simply Wall St. · Aug 24, 2026
- 제품·기술
Moderna Stock Had A Readout Waiting In Plain Sight
Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.
Trefis · Aug 24, 2026
홀더
ALNY 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
101.7%
기관 보유 (유동주식)
101.9%
내부자 보유
0.2%
기관 수
1,189
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| FMR, LLC | 15.02M | $3.62B | 11.2% | 3.0% | Jun 30, 2026 |
| Capital World Investors | 11.14M | $2.68B | 8.3% | 3.2% | Jun 30, 2026 |
| Blackrock Inc. | 10.91M | $2.63B | 8.1% | 4.4% | Jun 30, 2026 |
| Capital Research Global Investors | 9.75M | $2.35B | 7.3% | 2.9% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 6.54M | $1.57B | 4.9% | 0.7% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 6.03M | $1.45B | 4.5% | 1.4% | Jun 30, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.64M | $1.36B | 4.2% | 8.6% | Jun 30, 2026 |
| Invesco Ltd. | 3.75M | $903.63M | 2.8% | -7.9% | Jun 30, 2026 |
| State Street Corporation | 3.56M | $855.82M | 2.7% | 7.0% | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 2.68M | $643.97M | 2.0% | -57.7% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.